Pharmaceutical Business Review
Regulatory Affairs
Anonymous User | Login

Cequent Files IND For CEQ508 With FDA

Published: 12-Nov-2009

Expects to begin phase I clinical trial in the FAP during the first quarter of 2010

Cequent Pharmaceuticals (Cequent) has filed an investigational new drug (IND) application with the FDA. CEQ508, an orally administered tkRNAi drug candidate, targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

Cequent expects to begin the phase I clinical trial in the FAP (familial adenomatous polyposis) patient population during the first quarter of 2010, at the Fred Hutchinson Cancer Research Center, in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium.

The company said that the clinical trial, as proposed to the FDA, would be conducted to determine safety and tolerability of CEQ508 at escalating doses in a total of 18 adult FAP patients.

A key readout and secondary objective of the proposed trial includes analysis of biomarker (beta-catenin) expression changes in the gastrointestinal tract of patients determined from biopsy samples taken prior to taking the drug, and following a daily, 28-day dosing regimen.

Reportedly, in preclinical testing with non-human primates, tkRNAi therapeutic candidates have demonstrated potent silencing of the beta-catenin, a protein known to accumulate and lead to the proliferation of polyps in affected patients. During preclinical testing, CEQ508 demonstrated an encouraging safety profile when administered as a daily oral therapeutic.

Peter Parker, CEO of Cequent, said: "A first IND filing is obviously a momentous event for a young company like Cequent, and this is also a critical milestone in the development of RNAi therapeutics in general, as our proposed Phase I trial will be the first test of an orally administered RNA interference drug in humans."

"We believe that our orally administered tkRNAi technology has shown great potential in solving that significant problem. We also continue to make important progress with our tkRNAi inflammatory bowel disease (IBD) program, for which this CEQ508 trial serves as a regulatory and safety pathbreaker. Cequent is moving ahead with preclinical development of tkRNAi products targeting immunological genes implicated in the pathology of IBD."

"We have now entered a new phase in the company's lifecycle; we have transitioned away from research to focus on our clinical programs, much of which we will pursue with contract resources. As such, we have promoted Alison Silva to the new position of vice president of drug development, overseeing all clinical development and regulatory affairs for the company. Co-inventor of the tkRNAi technology, Johannes Fruehauf, will support the upcoming clinical trial through a consultancy arrangement as vice president of medical affairs," he added."

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Adis

Independently Evaluated Drug Information ...

Aris Global

Integrated Software Solutions and Services for Life Sciences ...

Axiom Real Time Metrics

EDC Solutions ...

BioClinica

Global Clinical Trial Solutions. Real-World Results ...

BIOQUELL

Specialist Providers of Bio-decontamination Equipment and Services ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

No items to display

Suppliers Product News

BioClinica's Express Platform Receives CDISC Certification

Bio-Imaging Technologies, Inc., (NASDAQ: BITI) d/b/a BioClinica, a leading global provider of clinical trial services, has announced that its Express EDC platform has been certified by the Clinical Data Interchange Standard Consortium (CDISC) as complying with the Operational Data Model (ODM) standard.

Bio-Imaging Technologies, Inc. Shareholders Approve Company's Name Change to BioClinica, Inc.

Bio-Imaging Technologies, Inc. (NASDAQ: BITI), a global provider of clinical trial services, has received shareholder approval to change its name to BioClinica, Inc., effective immediately.

Bioclinica's Jonathan Andrus Named Chair of DIA's eClinicall SIAC

Bio-Imaging Technologies, Inc., (NASDAQ: BITI) d/b/a BioClinica a leading global provider of clinical trial services, announced today that Jonathan Andrus, vice president, clinical data management & regulatory operations at BioClinica's eClinical service division, has been elected as the Drug Information Association (DIA) North American Special Interest Area Communities (SIAC) eClinical Chair.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address